Inside the Dr. Jart+ Acquisition Talks
PTA Partners, a private equity firm, is pursuing a joint acquisition of Have & Be, the company behind Dr. Jart+, from Estée Lauder. The potential Dr. Jart+ acquisition would mark a return to local ownership after several years under a global conglomerate. According to reports, PTA Partners is working with domestic strategic investors, including indie beauty brands, while global investment banks Evercore and JPMorgan supervise the sale process. The business is valued at more than 200 billion won, highlighting the remaining strategic appeal of the brand despite recent challenges. Estée Lauder completed its own acquisition of Dr. Jart+ in 2019, but the brand’s performance has deteriorated since then. The current talks suggest a turning point: a shift from management within a broad multinational portfolio to a more focused, locally steered model that could better align with fast-moving K-beauty market trends.
From Global Conglomerate to Local Steward: Why Ownership Matters
Estée Lauder’s divestment considerations follow a period of weak performance at Have & Be, with revenue sliding from 634.7 billion won and an operating profit of 121.4 billion won in 2019 to revenue of 178.8 billion won and an operating loss of 23.2 billion won last year. Industry observers argue that the conglomerate struggled to keep pace with shifting beauty preferences and allowed domestic marketing to weaken. A return to local ownership could reverse some of these issues. Korean beauty brand ownership often brings tighter integration with local innovation clusters, faster decision-making, and a more instinctive feel for consumer shifts in ingredients, formats, and textures. For Dr. Jart+, a brand originally celebrated for dermatologist-inspired formulas and disruptive packaging, this change could enable a re-centering on its core identity rather than forcing it to conform to global portfolio priorities and standardized playbooks.
Reviving Strategy: R&D, Product Pipelines, and Marketing
PTA Partners believes it can reignite growth by anchoring Dr. Jart+ more deeply within the country’s advanced beauty ecosystem. This includes sophisticated ODM and OEM manufacturing capabilities, which can accelerate product development and experimentation across skincare categories. A renewed focus on R&D could see the brand double down on dermatological claims, barrier-care concepts, and high-performance ingredients that once differentiated it in the crowded K-beauty field. On the commercial side, leveraging global influencer marketing and creator-led storytelling can help restore buzz, particularly among younger consumers. The failure to adapt quickly under Estée Lauder exposed how critical speed and cultural fluency are in beauty today. Under new ownership, Dr. Jart+ could test niche collections, limited drops, and region-specific innovations more aggressively, reducing reliance on legacy hero products and aligning more closely with dynamic K-beauty market trends worldwide.
What This Means for K‑Beauty’s Global Playbook
The proposed deal fits into a wider narrative of Korean beauty brand ownership evolving alongside globalization. Many leading labels have partnered with or sold stakes to multinational groups to unlock distribution scale and capital. Yet Dr. Jart+ shows that global backing does not guarantee sustainable growth if local agility and trend sensitivity are diluted. PTA Partners’ broader investment strategy across Korea and Europe suggests a hybrid model: building beauty champions that remain culturally rooted while competing internationally. If the acquisition succeeds and the turnaround is convincing, it may encourage other K‑beauty players to rethink how they balance foreign capital with local control. For global investors, Estée Lauder’s divestment could serve as a cautionary case, underscoring the need to preserve on-the-ground expertise and innovation speed when integrating distinctively positioned K‑beauty brands into large, global portfolios.